Výsledky vyhledávání

Abstract P1-16-05: Oraxol + Encequidar (OPac+E) vs IV paclitaxel (IVPac) in the treatment of patients with metastatic breast cancer (mBC) (Study KX-ORAX-001): Subgroup survival analysis of patients with hepatic dysfunction

Autor: Gerardo Umanzor, Hope S Rugo, Francisco J Barrios, R H Vasallo, Marco A Chivalan, S Bejarano, Julio Roberto Ramirez, Luis Fein, R D Kowalyszyn, D L Cutler, D Kramer, H Wang, R MF Kwan

Publikováno v: Cancer Research. 82:P1-16

Background: IVPac is widely used to treat patients with breast cancer. oPac+E is oral paclitaxel in combination with Encequidar, an oral, minimally absorbed, specific p-glycoprotein inhibitor that enables the absorption of oral paclitaxel. Results of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1d38383fb942a80deb271ccf0db35570
https://doi.org/10.1158/1538-7445.sabcs21-p1-16-05

Zobrazit plný text záznamu

Abstract PD1-08: Oral paclitaxel and encequidar (oPac+E) versus IV paclitaxel (IVPac) in the treatment of metastatic breast cancer (mBC) patients (study KX-ORAX-001): Progression free survival (PFS) and overall survival (OS) updates

Autor: D L Cutler, J R Ramirez, Hope S. Rugo, R D Kowalyszyn, Suyapa A. Bejarano, R H Vasallo, J Goldfinch, G Umanzor, F J Barrios, R Mf Kwan, D Kramer, Hui Wang, M A Chivalan, Luis Fein, T Moore

Publikováno v: Cancer Research. 81:PD1-08

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::21d20ea0a81167c6cd6de4637dbe97c8
https://doi.org/10.1158/1538-7445.sabcs20-pd1-08

Zobrazit plný text záznamu

Abstract PS13-06: Lower rates of neuropathy with oral paclitaxel and encequidar (oPac+E) compared to IV paclitaxel (IVPac) in treatment of metastatic breast cancer (mBC): Study KX-ORAX-001

Autor: Suyapa A. Bejarano, F J Barrios, R H Vasallo, D Kramer, G Umanzor, R Mf Kwan, J Goldfinch, T Moore, M A Chivalan, D L Cutler, Luis Fein, R D Kowalyszyn, J R Ramirez, Hui Wang, Hope S. Rugo

Publikováno v: Cancer Research. 81:PS13-06

Background: Chemotherapy-induced peripheral neuropathy (CIPN) is a common dose-limiting toxicity associated with IVPac. Primarily sensory, CIPN is an often irreversible condition primarily affecting the hands and feet associated with pain, numbness,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::83c2ef5eb2fc0f66862fa6d73b4aec08
https://doi.org/10.1158/1538-7445.sabcs20-ps13-06

Zobrazit plný text záznamu

Abstract PS13-11: Oral paclitaxel and encequidar (oPac+E) in the treatment of metastatic breast cancer (mBC): Management of gastrointestinal adverse events (GI AE). Study KX-ORAX-001

Autor: D L Cutler, R D Kowalyszyn, Hope S. Rugo, D Kramer, Hui Wang, F J Barrios, Suyapa A. Bejarano, R H Vasallo, T Moore, J R Ramirez, J Goldfinch, G Umanzor, R Mf Kwan, M A Chivalan, Luis Fein

Publikováno v: Cancer Research. 81:PS13-11

Background: There is a need for more effective and less toxic treatments for patients with mBC. Patients may prefer oral vs IV cytotoxic therapies to avoid frequent hospital visits. In addition, oral therapies allow frequent or metronomic dosing regi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::65c6b699257a7cd17ddc97db8a5259ca
https://doi.org/10.1158/1538-7445.sabcs20-ps13-11

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání